The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
BACKGROUND
Asoprisnil is a selective progesterone receptor modulator with mixed progesterone agonist/antagonist activity which controls uterine bleeding via an endometrial effect. This study examined full-thickness endometrial, leiomyoma and myometrial morphology in hysterectomy specimens from patients with uterine leiomyomata, after treatment with asoprisnil for 3 months.


METHODS
In this double-blind, randomized, placebo-controlled study, 33 subjects with uterine leiomyomata were randomized to receive asoprisnil 10, 25 mg or placebo for an average of 95 days prior to hysterectomy. Samples of endometrium, myometrium and leiomyoma tissue were subjected to systematic morphological assessment with quantification of mitotic activity.


RESULTS
In patients treated with 10 or 25 mg asoprisnil, a unique pattern called 'non-physiologic secretory effect' was evident in endometrium, recognizable through partially developed secretory glandular appearances and stromal changes. Endometrial thickness was decreased, and there were low levels of mitotic activity in endometrial glands and stroma. Unusual thick-walled muscular arterioles and prominent aggregations of thin-walled vessels were present in endometrial stroma, but not in myometrium or non-endometrial vascular beds. Mitotic activity was decreased in leiomyomata.


CONCLUSIONS
Asoprisnil induces unique morphological changes and is associated with low levels of glandular and stromal proliferation in endometrium, and in leiomyomata. These changes are likely to contribute to the amenorrhoea experienced after exposure to the medication.
Williams
A R W
AR
Department of Pathology, University of Edinburgh, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, Scotland, UK. a.williams@ed.ac.uk
Critchley
H O D
HO
Osei
J
J
Ingamells
S
S
Cameron
I T
IT
Han
C
C
Chwalisz
K
K
D000328:Adult; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D004963:Estrenes / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D009215:Myometrium / Q000187:drug effects / Q000473:pathology; D010091:Oximes / Q000008:administration & dosage / Q000009:adverse effects*; D010919:Placebos; D011980:Receptors, Progesterone / Q000187:drug effects*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology*; D014599:Uterus / Q000187:drug effects* / Q000473:pathology*
D004963:Estrenes; D010091:Oximes; D010919:Placebos; D011980:Receptors, Progesterone; C488516:asoprisnil